Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 7.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.27% |
| Mar 31, 2026 | 30.42% |
| Dec 31, 2025 | -43.73% |
| Sep 30, 2025 | 26.20% |
| Jun 30, 2025 | -79.68% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | 30.57% |
| Sep 30, 2024 | 30.44% |
| Jun 30, 2024 | 53.07% |
| Mar 31, 2024 | 35.70% |
| Dec 31, 2023 | 26.14% |
| Sep 30, 2023 | 37.71% |
| Jun 30, 2023 | 60.09% |
| Mar 31, 2023 | 23.80% |
| Dec 31, 2022 | 64.17% |
| Sep 30, 2022 | 0.30% |
| Jun 30, 2022 | 35.83% |
| Mar 31, 2022 | 4.28% |
| Dec 31, 2021 | -4.30% |
| Sep 30, 2021 | -31.73% |